GGrantIndex
← Search

Informatics Shared Resource

$186,386P30FY2013CANIH

Vanderbilt University, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

The mission of the Vanderbilt-lngram Cancer Center Informatics Shared Resource (ISR) is to catalyze the research productivity of VICC investigators by providing two essential ingredients for success. The first is a flexible physical and electronic infrastructure for acquiring, storing, communicating and analyzing data arising from wet bench, translational, and clinical cancer research. The second is assistance by senior-level staff and faculty in the interpretation of research datasets using state-of-the-art analysis methods where they are available, and the development of novel bioinformatics methods where current analytical approaches are insufficient. The ISR in its current form has evolved from the Tissue Clinical Informatics Shared Resource that was created during the preceding grant period. That resource had a focus on the informatics of characterization, annotation and tracking of tissue samples associated with clinical trials and basic research. At the time of the last competitive renewal, this shared resource received an Outstanding rating. We have broadened the scope of the resource to support all of the basic, translational and clinical research of VICC, thus leading to our renaming ofthe resource in the current application. The resource has been strengthened by two new faculty hires - Mia Levy, M.D., and Zhongming Zhao, Ph.D. Dr. Levy is a Stanford-trained medical oncologist with a Master's degree in Biomedical Informatics who serves as the VICC Clinical Informatics faculty lead for development and deployment of advanced clinical research and cancer care systems. Dr. Zhao is Chief Bioinformatics Officer for VICC and heads a new Bioinformatics Data Interpretation service available to Center Investigators. Dan Masys, M.D., a medical oncologist and chair of Vanderbilt's Department of Biomedical Informatics, leads the resource, and Scott Sobecki, an experienced senior information technology professional, directs a team of in-house programmers and systems support staff. The ISR benefits from the information technology resources of Vanderbilt University Medical Center, which provide a fertile environment for informatics innovations in support of basic, translational and clinical cancer research, and cancer care that will measurably advance the state of the art.

View original record on NIH RePORTER →